You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Patient profile

Meet Gabrielle

I’ve got used to often being short of breath, so I no longer go for my morning walks

Age: 56 years

FEV1 predicted: 63%

mMRC: 2

GOLD B

Current treatment: As-needed short-acting β2 agonist (SABA)

Gabrielle was diagnosed with chronic obstructive pulmonary disease (COPD) one year ago. Despite taking a SABA, she remains symptomatic.

For information on assessing your breathless patient, click here.

Continued breathlessness on exertion is proven to compromise patients’ daily life

  • 70%–74% of patients with mild or moderate breathlessness experience limitations in routine activities, such as walking to the shops 1
  • COPD may eventually limit patient mobility both inside and outside of the home, and is associated with feelings of panic, anxiety and depression 23
  • Around 40% of patients are forced to retire early due to their symptoms 4

Indication

Incruse Ellipta (umeclidinium) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. 4

Before prescribing please consult the full SPC which you can request from GSK or access on the website of the Pharmaceutical Services of the Ministry of Health http://www.phs.moh.gov.cy/web/guest/drug-search

References:

  1. Jones PW et al. Respir Med 2011; 105:57–66.
  2. Price D et al. Prim Care Respir J 2005; 14:285–293.
  3. Jolley CJ & Moxham J. Eur Respir Rev 2009; 18:66–79.
  4. Fletcher MJ et al. BMC Public Health 2011; 11:612.
  5. Incruse Ellipta SmPC

Trade marks are owned by or licensed to the GSK group of companies.
© 2018 GSK group of companies or its licensor.